Postinfectious Immune-Mediated Neurological Diseases

  • Marios HadjivassiliouEmail author
  • Panagiotis Zis
Part of the Contemporary Clinical Neuroscience book series (CCNE)


Infection may trigger immune-mediated neurological dysfunction. In some specific examples, the pathogenesis has been clearly delineated, with a detrimental effect of the immune response to infection. This chapter will cover immune-mediated neurological diseases where infection is the antigenic trigger. Postinfectious cerebellitis, Miller Fisher syndrome, acute disseminated encephalomyelitis, vasculitis and Guillain-Barré syndrome (GBS) are discussed, from the clinical presentation to therapies. Presentation may be monophasic (e.g. GBS) or sometimes evolve into a chronic condition (e.g. vasculitis). In some cases, the prognosis is excellent with full recovery. In others, patients will develop permanent neurological deficits. Therapies are often based on steroids, plasma exchange and intravenous immunoglobulins. Despite a favourable clinical course, postinfectious cerebellitis may rarely require surgical decompression due to oedema of the posterior fossa. Treatment should be initiated as fast as possible.


Postinfectious Cerebellitis Vasculitis Miller Fisher syndrome Guillain-Barré syndrome Acute disseminated encephalomyelitis ADEM 


  1. 1.
    Marchioni E, Ravaglia S, Montomoli C, et al. Postinfectious neurologic syndromes: a prospective cohort study. Neurology. 2013;80:882–900.CrossRefGoogle Scholar
  2. 2.
    Batten FE. Ataxia in childhood. Brain. 1905;87:141–52.Google Scholar
  3. 3.
    Kennedy PGE. Neurological complications of varicella zoster virus. In: Kennedy PGE, Johnson RT, editors. Infections of the nervous system. London: Butterworths; 1987. p. 177–208.CrossRefGoogle Scholar
  4. 4.
    Connolly AM, Dodson WE, Prensky AL, et al. Course and outcome of acute cerebellar ataxia. Ann Neurol. 1994;35:673–9.CrossRefGoogle Scholar
  5. 5.
    Klockgether T, Döller G, Wüllner U, et al. Cerebellar encephalitis in adults. J Neurol. 1993;240:17–20.CrossRefGoogle Scholar
  6. 6.
    De Silva HJ, Hoang P, Dalton H, et al. Immune activation during cerebellar dysfunction following Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 1992;86:129–31.CrossRefGoogle Scholar
  7. 7.
    Ito H, Sayama S, Irie S, et al. Antineuronal antibodies in acute ataxia following Epstein-Barr infection. Neurology. 1994;44:1506–7.CrossRefGoogle Scholar
  8. 8.
    Sawaishi Y, Takada G. Acute cerebellitis. Cerebellum. 2002;1:223–8.CrossRefGoogle Scholar
  9. 9.
    Fisher CM. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255:57–65.CrossRefGoogle Scholar
  10. 10.
    Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104–6.CrossRefGoogle Scholar
  11. 11.
    Al-Din SN, Anderson M, Eeg-Olofsson O, et al. Neuro-ophthalmic manifestations of the syndrome of ophthalmoplegia, ataxia and areflexia: a review. Acta Neurol Scand. 1994;89:157–63.CrossRefGoogle Scholar
  12. 12.
    Urushitani M, Udaka F, Kameyama M. Miller Fisher Guillain-Barre overlap syndrome with enhancing lesions in the spinocerebellar tracts. J Neurol Neurosurg Psychiatry. 1995;58:241–3.CrossRefGoogle Scholar
  13. 13.
    Lo YL. Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve. 2007;36:615–27.CrossRefGoogle Scholar
  14. 14.
    Kim YK, Kim JS, Jeong SH, et al. Cerebral glucose metabolism in Fisher syndrome. J Neurol Neurosurg Psychiatry. 2009;80:512–7.CrossRefGoogle Scholar
  15. 15.
    Kornberg AJ, Pestronk A, Blume GM, et al. Selective staining of the cerebellar molecular layer by serum of Miller Fisher and related syndromes. Neurology. 1996;47:1317–20.CrossRefGoogle Scholar
  16. 16.
    Berlit P, Rakicky J. The Miller Fisher syndrome. Review of the literature. J Clin Neuroophthalmol. 1992;12:57–63.PubMedGoogle Scholar
  17. 17.
    Sandler RD, Hoggard N, Hadjivassiliou M. Miller-Fisher syndrome: is the ataxia central or peripheral? Cerebellum Ataxias. 2015;2:3.CrossRefGoogle Scholar
  18. 18.
    Hahn AF. Guillain-Barre syndrome. Lancet. 1998;352:635–41.CrossRefGoogle Scholar
  19. 19.
    O'Leary CP, Willison HJ. Autoimmune ataxic neuropathies (sensory ganglionopathies). Curr Opin Neurol. 1997;10:366–70.CrossRefGoogle Scholar
  20. 20.
    Mori M, Kuwabara S, Fukutake T, et al. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007;68:1144–6.CrossRefGoogle Scholar
  21. 21.
    Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72(3):232–9.CrossRefGoogle Scholar
  22. 22.
    Benneto L, Scolding N. Inflammatory/post-infectious encephalomyelitis. J Neurol Neurosurg Psychiatry. 2004;75:i22–8.CrossRefGoogle Scholar
  23. 23.
    Young NP, Weinshenker BG, Parisi JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. 2010;133:333–48.CrossRefGoogle Scholar
  24. 24.
    Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis. A follow up study of 40 adult patients. Neurology. 2001;56:1313–8.CrossRefGoogle Scholar
  25. 25.
    Pleister A, Eckels DD. Cryptic infection and autoimmunity. Autoimmun Rev. 2003;2:126–32.CrossRefGoogle Scholar
  26. 26.
    Belizna CC, Hamidou MA, Levesque H, et al. Infection and vasculitis. Rheumatology (Oxford). 2009;48:475–82.CrossRefGoogle Scholar
  27. 27.
    Guillevin L, Lhote F, Leon A, Feuvelle F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol. 1993;20:289–98.PubMedGoogle Scholar
  28. 28.
    Cacoub P, Maisonobe T, Thibault V, et al. Systemic vasculitis in patients with hepatitis C. Rheumatology. 2001;28:109–18.Google Scholar
  29. 29.
    Pagnoux C, Cohen P, Guillevin L. Vasculitides secondary to infections. Clin Exp Rheumatol. 2006;24:S71–81.PubMedGoogle Scholar
  30. 30.
    Wucherpfenning KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest. 2001;108:1097–104.CrossRefGoogle Scholar
  31. 31.
    Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–27.CrossRefGoogle Scholar
  32. 32.
    Huizinga R, van den Berg B, van Rijs W, Tio-Gillen AP, Fokkink WJ, Bakker-Jonges LE, Geleijns K, Samsom JN, van Doorn PA, Laman JD, Jacobs BC. Innate immunity to Campylobacter jejuni in Guillain-Barré syndrome. Ann Neurol. 2015;78(3):343–54.CrossRefGoogle Scholar
  33. 33.
    Winer JB. Guillain-Barré syndrome. BMJ. 2008;337:a671. Scholar
  34. 34.
    Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43.CrossRefGoogle Scholar
  35. 35.
    Artemiadis AK, Zis P. Neuropathic Pain in Acute and Subacute Neuropathies: A Systematic Review. Pain Physician. 2018;21(2):111–20.PubMedGoogle Scholar
  36. 36.
    Winer JB, Hughes RA. Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome. Quart J Med. 1988;68:735–9.PubMedGoogle Scholar
  37. 37.
    Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2017;88(4):346–52.CrossRefGoogle Scholar
  38. 38.
    Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998;64:74–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Academic Department of NeurosciencesRoyal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust and University of SheffieldSheffieldUK

Personalised recommendations